Company / R&D Expense
MBX Biosciences, Inc. R&D Expense History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$57.4M
FY2024
5-year range
$28.5M / $57.4M
FY2023-FY2024
Trend
+101.2%
vs FY2023
Sector context
#175 of 210
Health Care
What the data says
MBX Biosciences, Inc.'s r&d expense of $57M is lower than 83% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
$57M in FY2024.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 17% in Health CareTop 83% of 210This company $57.4M Sector average $644.1M
▼
-91.1% below sector average
Key checks
Key Insights
- In FY2024, r&d expense increased 101.2% year-over-year.
- Ranks #175 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 9.64 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $57.4M | +101.2% |
| FY2023 | $28.5M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026